Grants Portal

Oncopeptides is committed to support external organisations to improve health and the healthcare community, access to care, to help advance scientific breakthroughs and improve the lives of patients with difficult-to-treat hematological diseases.

Due to the recent news that Oncopeptides has voluntarily withdrawn PEPAXTO® in the U.S. and will close the U.S. commercial business unit, we will not consider any grants for 2022, unfortunately. We sincerely thank you for your support and interest in Oncopeptides and the treatment of patients with relapsed or refractory multiple myeloma.